Lebwohl David 4
4 · Intellia Therapeutics, Inc. · Filed Jan 5, 2024
Insider Transaction Report
Form 4
Lebwohl David
EVP, Chief Medical Officer
Transactions
- Sale
Common Stock
2024-01-03$29.46/sh−5,843$172,135→ 54,372 total
Footnotes (1)
- [F1]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person.